Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).

被引：1
|
作者：
Rini, Brian I.
Escudier, Bernard
Murphy, Danielle
Wang, Panpan
Tarazi, Jamal Christo
Motzer, Robert J.
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Univ Paris Saclay, Gustave Roussy, Med Oncol, Villejuif, France
[3] Pfizer Oncol, La Jolla, CA USA
[4] Pfizer Oncol, Shanghai, Peoples R China
[5] Pfizer Oncol, San Diego, CA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.614
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
614
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)
    McDermott, D. F.
    Infante, J. R.
    Chowdhury, S.
    Voss, M. H.
    Motzer, R. J.
    Perini, R. F.
    Morosky, A.
    Zheng, F. F.
    White, B. C.
    Wang, Q.
    Jewell, R. C.
    Rini, B. I.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S519 - S520
  • [32] EXPLORATION OF SERUM BIOMARKERS TO PREDICT AXITINIB EFFICACY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Honma, Naoko
    Tsuchiya, Norihiko
    Inoue, Takamitsu
    Nara, Taketoshi
    Kanda, Sohei
    Numakura, Kazuyuki
    Tsuruta, Hiroshi
    Saito, Mitsuru
    Narita, Shintaro
    Satoh, Shigeru
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1068 - E1068
  • [33] Genetic evaluation of fatigue in pazopanib-treated patients (pts) with advanced renal cell carcinoma (RCC).
    Glass, S. M.
    Huang, L.
    King, K.
    Ragone, L. J.
    Ball, H. A.
    De Souza, P. L.
    Wagstaff, J.
    Spraggs, C. F.
    Mooser, V. E.
    Pandite, L. N.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF THE TWO MULTI-KINASE INHIBITORS, SORAFENIB AND SUNITINIB, IN PATIENTS (PTS) WITH ADVANCED RENAL CELL CARCINOMA (ARCC)
    Porta, Camillo
    Procopio, Giuseppe
    Carteni, Giacomo
    Sabbatini, Roberto
    Bearz, Alessandra
    Chiappino, Isabella
    Ruggeri, Enzo Maria
    Lo Re, Giovanni
    Landi, Lorenza
    Calcagno, Anna
    Imarisio, Ilaria
    Paglino, Chiara
    Verzoni, Elena
    Guadalupi, Valentina
    Rizzo, Mimma
    Canipari, Cinzia
    Bajetta, Emilio
    ANNALS OF ONCOLOGY, 2009, 20
  • [35] Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Albiges, Laurence
    Haanen, John B. A. G.
    Larkin, James M. G.
    Uemura, Motohide
    Pal, Sumanta K.
    Gravis, Gwenaelle
    Campbell, Matthew T.
    Penkov, Konstantin
    Lee, Jae-Lyun
    Ching, Keith A.
    Mu, Xinmeng Jasmine
    Wang, Xiao
    Zhang, Weidong
    Wang, Jing
    Chudnovsky, Aleksander
    di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Chowdhury, Simon
    McDermott, David F.
    Voss, Martin Henner
    Hawkins, Robert E.
    Aimone, Paola
    Voi, Maurizio
    Isabelle, Naeije
    Wu, Vi
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Treatment beyond progression with nivolumab (nivo in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.
    Escudier, Bernardi.
    Motzer, Roberti.
    Sharma, Padmanee
    Wagstaff, John
    Plimack, Elizabeth R.
    Hammers, Hans J.
    Donskov, Frede
    Gurney, Howard
    Sosman, Jeffrey Alan
    Zalewski, Pawel
    Harmenberg, Ulrika
    McDermott, David F.
    Choueiri, Toni K.
    Richardet, Martin Eduardo
    Tomita, Yoshihiko
    Ravaud, Alain
    Doan, Justin
    Zhao, Huanyu
    Hardy, Helene
    George, Saby
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Clinical outcome differences based on gender in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs)
    Choi, Yujin
    Goswamy, Rohit Vivek
    Wei, Mengting
    Liu, Yuan
    Yildirim, Ahmet
    Brown, Jacqueline T.
    Nazha, Bassel
    Martini, Dylan J.
    Hartman, Caitlin
    McClintock, Greta Russler
    Zhuang, Tony
    Kissick, Haydn
    Harris, Wayne B.
    Carthon, Bradley Curtis
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3
    Meza, Luis
    McDermott, David F.
    Escudier, Bernard
    Hutson, Thomas E.
    Porta, Camillo
    Verzoni, Elena
    Atkins, Michael B.
    Kasturi, Vijay
    Pal, Sumanta K.
    Rini, Brian
    ONCOLOGIST, 2022, : e167 - e170
  • [40] Axitinib In Advanced, Treatment-Experienced Renal Cell Carcinoma
    Yang, Lily P. H.
    McKeage, Kate
    DRUGS, 2012, 72 (18) : 2375 - 2384
12345